TETRAGENEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 333-134987 22-3781895
(State or other jurisdiction
of incorporation) (Commission
File Number) (IRS Employer
Identification No.)
560 SYLVAN AVENUE, 3 RD FLOOR
ENGLEWOOD CLIFFS, NJ 07632
(Address of principal executive offices and Zip Code)
(201) 408-5335
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
INFORMATION ABOUT FORWARD-LOOKING STATEMENTS
Item 1.03 Bankruptcy or Receivership
As previously disclosed by Tetragenex Pharmaceuticals, Inc. (the “Company”), in the Company’s Form 10-Q for the quarter ended June 30, 2009, filed with the Securities and Exchange Commission on August 13, 2009, on August 10, 2009 the Company filed for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of New Jersey (the “Bankruptcy Court”), Case No. 09-30775.
On November 2, 2009, the Company received notice that the Bankruptcy Court dismissed its request for relief under Chapter 11 of the Bankruptcy Code (the “Order”).
The foregoing summary of the Order is qualified in its entirety by reference to the definitive court documents, copies of which are attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1 Order from the United States Bankruptcy Court District of New Jersey, dated November 2, 2009.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TETRAGENX PHARMACEUTICALS, INC.
/s/ Martin F. Schacker
Martin F. Schacker
Co-Chief Executive
